HPV guidance depends on follow-up

WHO’s May 8 guideline ties HPV genotyping choices to a programme’s capacity for follow-up and treatment. New recommendations for the general population of women are conditional, based on low-certainty evidence from review and modelling. It adds no extended-genotyping recommendation for women living with HIV, whose outcomes were not evaluated. More visits can increase losses to follow-up; finer test categories alone do not complete care. ^[1]

The distinction builds on WHO’s 2020 elimination strategy. Its 2030 targets include screening 70% of women with a high-performance test by age 35 and again by 45, alongside treatment for 90% of those identified with cervical disease. Those are linked coverage goals, not a claim that they have been achieved. Counting tests without the subsequent care would leave the strategy incomplete. ^[2]

WHO’s July 2026 clinical reference explains why a positive HPV screen is not itself a cancer diagnosis. Most infections clear naturally; persistent infection with carcinogenic types can produce abnormal cells that progress over years. Follow-up examines whether precancerous changes are present. That biological sequence makes both risk classification and access to further assessment consequential, without making every infection equivalent to cancer. ^[3]

About this item: Retrospective report. No first-hand reporting or independent testing is claimed. Corrections policy.